NVS: Novartis AG Stocks News on September 15, 2025

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

NVS

Insider Monkey

5 hours ago

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

NVS

MT Newswires

5 hours ago

Traders Cautious Ahead of Fed Meeting, Driving Muted Premarket Action for US Equity Futures

NVS

The Bergen Record

5 hours ago

3 firms to lay off hundreds of North Jersey-based employees

NVS

Investing.com

6 hours ago

Monte Rosa surges premarket on Novartis collaboration deal

NVS

MT Newswires

7 hours ago

Top Premarket Gainers

NVS

MT Newswires

7 hours ago

Monte Rosa Therapeutics Partners With Novartis on Immune Disease Degraders; Shares Rise Pre-Bell

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

NVS

Reuters

7 hours ago

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

NVS

GlobeNewswire

7 hours ago

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Molson Coors downgraded, GM upgraded: Wall Street's top analyst calls

NVS

The Fly

3 days ago

Molson Coors downgraded, GM upgraded: Wall Street's top analyst calls

More leaders are recognizing the ‘power of small teams’

NVS

Fortune

3 days ago

More leaders are recognizing the ‘power of small teams’

NVS

Zacks

4 days ago

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

NVS

Simply Wall St.

5 days ago

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

Top 20 biopharma market caps fall 5.7% amid industry challenges

NVS

Pharmaceutical Technology

5 days ago

Top 20 biopharma market caps fall 5.7% amid industry challenges

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

NVS

Zacks

5 days ago

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

NVS

Zacks

5 days ago

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More

NVS

GlobeNewswire

5 days ago

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

NVS

Pharma Voice

5 days ago

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)

NVS

Insider Monkey

6 days ago

H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)

Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal

NVS

GuruFocus.com

6 days ago

Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'

NVS

Investor's Business Daily

6 days ago

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'

NVS

MT Newswires

6 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

NVS

MT Newswires

6 days ago

Sector Update: Health Care

NVS

MT Newswires

6 days ago

Top Midday Gainers

3 firms to lay off hundreds of North Jersey-based employees

NVS

The Bergen Record

6 days ago

3 firms to lay off hundreds of North Jersey-based employees

NVS

MT Newswires

6 days ago

Tourmaline Bio Agrees to $1.4 Billion Takeover by Novartis

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

NVS

The Wall Street Journal

7 days ago

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

Novartis to acquire Tourmaline Bio for $1.4 billion

NVS

Reuters

7 days ago

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

NVS

GlobeNewswire

7 days ago

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

NVS

GlobeNewswire

7 days ago

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

NVS

Zacks

7 days ago

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

BofA: Palantir's AIPCon 8 Highlighted 'Competitive Advantages.' Is Palantir A Buy?

NVS

Investor's Business Daily

7 days ago

BofA: Palantir's AIPCon 8 Highlighted 'Competitive Advantages.' Is Palantir A Buy?

This Warren Buffett Stock, Two Others, Hit New Highs

NVS

Investor's Business Daily

10 days ago

This Warren Buffett Stock, Two Others, Hit New Highs

NVS

Zacks

10 days ago

The Zacks Analyst Blog Highlights Apple, Novartis, Charles Schwab, Community Bancorp and Optex Systems

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal

NVS

Motley Fool

10 days ago

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal

Palantir Hosts Eighth AIPCon Amid OpenAI Worries. Is Palantir A Buy?

NVS

Investor's Business Daily

10 days ago

Palantir Hosts Eighth AIPCon Amid OpenAI Worries. Is Palantir A Buy?

Acetaminophen Market Trends and Forecasts, 2023-2024 & 2025-2033 | Rising OTC Demand, Wider Access to Essential Medicines, and Growth in Combination Therapies Drive Expansion

NVS

GlobeNewswire

10 days ago

Acetaminophen Market Trends and Forecasts, 2023-2024 & 2025-2033 | Rising OTC Demand, Wider Access to Essential Medicines, and Growth in Combination Therapies Drive Expansion

Top Stock Reports for Apple, Novartis & Charles Schwab

NVS

Zacks

11 days ago

Top Stock Reports for Apple, Novartis & Charles Schwab

Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?

NVS

Zacks

11 days ago

Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?

RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033, Report by DataM Intelligence

NVS

PR Newswire

11 days ago

RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033, Report by DataM Intelligence

Valley National Bank, drugmaker Novartis announce New Jersey layoffs

NVS

The Bergen Record

11 days ago

Valley National Bank, drugmaker Novartis announce New Jersey layoffs

Novartis adds again to siRNA pipeline with second deal in a day

NVS

Pharmaceutical Technology

11 days ago

Novartis adds again to siRNA pipeline with second deal in a day

NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy

NVS

Zacks

12 days ago

NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy

NVS

MT Newswires

12 days ago

Novartis Expands Pact With Argo Biopharmaceutical; Looks to Pick up Equity

Novartis licenses RNA drugs in deal with China-based Argo

NVS

BioPharma Dive

12 days ago

Novartis licenses RNA drugs in deal with China-based Argo

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

NVS

PR Newswire

12 days ago

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Aokah Appoints Robert Weltevreden to Board of Directors and Steve Rudderham as Chairperson of Advisory Board

NVS

PR Newswire

13 days ago

Aokah Appoints Robert Weltevreden to Board of Directors and Steve Rudderham as Chairperson of Advisory Board

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

NVS

Investor's Business Daily

13 days ago

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

NVS

MT Newswires

13 days ago

Update: Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced

NVS

Zacks Small Cap Research

13 days ago

ARWR: Signs Collaboration Agreement with Novartis with $200 Million Upfront…

Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda

NVS

GlobeNewswire

13 days ago

Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda

NVS

ACCESS Newswire

13 days ago

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

NVS

CNW Group

13 days ago

Aokah Appoints Robert Weltevreden to Board of Directors and Steve Rudderham as Chairperson of Advisory Board

NVS

MT Newswires

13 days ago

Arrowhead Pharmaceuticals Signs Deal With Novartis to Treat Synucleinopathies

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

NVS

Business Wire

13 days ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Startup Corsera Health aims to bring preventive heart medicine to the masses

NVS

BioPharma Dive

13 days ago

Startup Corsera Health aims to bring preventive heart medicine to the masses

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

NVS

Business Wire

14 days ago

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

Novartis (NVS) Strengthens Outlook With Ianalumab Trial Success and Leqvio Expansion

NVS

Insider Monkey

16 days ago

Novartis (NVS) Strengthens Outlook With Ianalumab Trial Success and Leqvio Expansion

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

NVS

GlobeNewswire

16 days ago

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

The Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma Expertise

NVS

Simply Wall St.

16 days ago

The Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma Expertise

NVS

PR Newswire

17 days ago

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up

NVS

Clinical Trials Arena

18 days ago

Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

18 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize

NVS

GlobeNewswire

19 days ago

Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize

Amylyx drug comes up short; Sanofi names new CMO

NVS

BioPharma Dive

19 days ago

Amylyx drug comes up short; Sanofi names new CMO

HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries

NVS

GlobeNewswire

19 days ago

HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

NVS

GlobeNewswire

19 days ago

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

NVS

GlobeNewswire

19 days ago

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

Autism Spectrum Disorder Market Research Report 2025-2035 | Expansion Spurred by Rising Prevalence, AI-Powered Diagnostics, Telehealth Expansion, and Adoption of Evidence-Based Therapies

NVS

GlobeNewswire

19 days ago

Autism Spectrum Disorder Market Research Report 2025-2035 | Expansion Spurred by Rising Prevalence, AI-Powered Diagnostics, Telehealth Expansion, and Adoption of Evidence-Based Therapies

NVS

MT Newswires

20 days ago

Novartis Commits $30 Million to BioArctic in BrainTransporter Licensing Pact

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

NVS

Zacks

20 days ago

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

Should Investors Rethink Tempus AI After Shares Double and New Novartis Collaboration?

NVS

Simply Wall St.

20 days ago

Should Investors Rethink Tempus AI After Shares Double and New Novartis Collaboration?

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

NVS

PR Newswire

21 days ago

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

NVS

Zacks

21 days ago

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

NVS

The Wall Street Journal

24 days ago

Health Care Roundup: Market Talk

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

NVS

GlobeNewswire

25 days ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

NVS

CNW Group

25 days ago

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

NVS

Morningstar Research

a month ago

Analyst Report: Alcon Inc.

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

NVS

Zacks

a month ago

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

QuisLex Appoints Alok Priyadarshi as Vice President, Strategic AI Advisory and Legal Transformation for QuisLex Advisory

NVS

GlobeNewswire

a month ago

QuisLex Appoints Alok Priyadarshi as Vice President, Strategic AI Advisory and Legal Transformation for QuisLex Advisory

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Will EXEL's Share Repurchase Program Boost Value for Investors?

NVS

Zacks

a month ago

Will EXEL's Share Repurchase Program Boost Value for Investors?

Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm

NVS

Business Wire

a month ago

Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm

New Novartis ESC data highlights strength of cardiovascular portfolio

NVS

GlobeNewswire

a month ago

New Novartis ESC data highlights strength of cardiovascular portfolio

Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO

NVS

Insider Monkey

a month ago

Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

NVS

Motley Fool

a month ago

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

NVS

Motley Fool

a month ago

2 Dividend Stocks to Buy and Hold

NVS

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise Late Afternoon

NVS

MT Newswires

a month ago

Novartis, Roche Reportedly Meet With Swiss Government Over US Tariffs

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

NVS

GlobeNewswire

a month ago

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

NVS

Zacks

a month ago

Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

NVS

Morningstar Research

a month ago

Analyst Report: Incyte Corporation

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

NVS

Zacks

a month ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Quantified Named to 2025 Inc. 5000, One of the 50 Fastest-Growing AI Firms in the U.S.

NVS

PR Newswire

a month ago

Quantified Named to 2025 Inc. 5000, One of the 50 Fastest-Growing AI Firms in the U.S.

Novartis scores again with third ianalumab Phase III victory

NVS

Clinical Trials Arena

a month ago

Novartis scores again with third ianalumab Phase III victory

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda

NVS

GlobeNewswire

a month ago

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda

NVS

The Wall Street Journal

a month ago

Health Care Roundup: Market Talk

NVS

Investing.com

a month ago

Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial

Novartis’s Ianalumab Meets Goals in Phase 3 Trial to Treat Autoimmune Disease

NVS

The Wall Street Journal

a month ago

Novartis’s Ianalumab Meets Goals in Phase 3 Trial to Treat Autoimmune Disease

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

NVS

GlobeNewswire

a month ago

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

NVS

MT Newswires

a month ago

Latest Novartis AG (NVS) News on September 15, 2025

Share on Social Networks: